{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:31:11Z","timestamp":1782556271915,"version":"3.54.5"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>At Bristol-Myers (BM) (1985\u20131990), John C. Martin started his HIV career with directing the clinical development of didanosine (ddI) and stavudine (d4T). During this period, he became aware of the acyclic nucleoside phosphonates (ANPs), such as (S)-HPMPA and PMEA, as potential antiviral drugs. Under his impulse, BM got involved in the evaluation of these ANPs, but the merger of BM with Squibb (to become BMS) incited John to leave BM and join Gilead Sciences, and the portfolio of the ANPs followed the transition. At Gilead, John succeeded in obtaining the approval from the US FDA for the use of cidofovir in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, which was reminiscent of John\u2019s first experience with ganciclovir (at Syntex) as an anti-CMV agent. At Gilead, John would then engineer the development of tenofovir, first as TDF (tenofovir disoproxil fumarate) and then as TAF (tenofovir alafenamide) and various combinations thereof, for the treatment of HIV infections (i), TDF and TAF for the treatment of hepatitis B (HBV) infections (ii), and TDF and TAF in combination with emtricitabine for the prophylaxis of HIV infections (iii).<\/jats:p>","DOI":"10.3390\/v13122410","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T03:21:05Z","timestamp":1638847265000},"page":"2410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/jm00359a023","article-title":"9-(1,3-Dihydroxy-2-propoxymethyl) guanine: A new potent and selective antiherpes agent","volume":"26","author":"Martin","year":"1983","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2\u2032,3\u2032-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0956462414554433","article-title":"A farewell to didanosine: Harm reduction and cost savings by eliminating use of didanosine","volume":"26","author":"Dziuban","year":"2015","journal-title":"Int. J. STD AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0000000000002119","article-title":"Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors","volume":"33","author":"Gelpi","year":"2019","journal-title":"AIDS"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4254\/wjh.v8.i36.1623","article-title":"Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study","volume":"8","author":"Logan","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2009.10.006","article-title":"Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides","volume":"85","author":"Martin","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2032,3\u2032-dideoxythymidine and its 2\u2032,3\u2032-unsaturated derivative (2\u2032,3\u2032-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90253-X","article-title":"Potent and selective in vitro activity of 3\u2032-deoxythymidin-2\u2032-ene (3\u2032-deoxy-2\u2032,3\u2032-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Schinazi","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14656566.2013.782285","article-title":"Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV\/AIDS","volume":"14","author":"Mateo","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Spaulding, A., Rutherford, G.W., and Siegfried, N. (2010). Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-na\u00efve individuals. Cochrane Database Syst. Rev., Cd008651.","DOI":"10.1002\/14651858.CD008651"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12004","article-title":"Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: A meta-analysis of 12,370 patients in 21 clinical trials","volume":"14","author":"Stephan","year":"2013","journal-title":"HIV Med."},{"key":"ref_13","first-page":"467","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Holy","year":"1986","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1073\/pnas.86.1.332","article-title":"Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent","volume":"86","author":"Balzarini","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/AAC.32.7.1025","article-title":"Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents","volume":"32","author":"Pauwels","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0166-3542(93)90050-S","article-title":"Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection","volume":"21","author":"Heijtink","year":"1993","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1128\/AAC.34.7.1326","article-title":"Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro","volume":"34","author":"Yokota","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/095632029400500201","article-title":"Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HB611 cells","volume":"5","author":"Yokota","year":"1994","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/AAC.35.2.394","article-title":"Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis","volume":"35","author":"Yokota","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042560-199804010-00008","article-title":"Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS","volume":"17","author":"Lalezari","year":"1998","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00042560-199700001-00006","article-title":"Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis","volume":"14","author":"Lalezari","year":"1997","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1073\/pnas.88.11.4961","article-title":"9-[(2RS)-3-Fluoro-2-phosphonylmethoxypropyl] derivatives of purines: A class of highly selective antiretroviral agents in vitro and in vivo","volume":"88","author":"Balzarini","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lou, L.L., and Martin, J.C. (2021). Selected thoughts on hydrophobicity in drug design. Molecules, 26.","DOI":"10.3390\/molecules26040875"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"Deeks","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00126334-200108150-00005","article-title":"Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408","volume":"27","author":"Miller","year":"2001","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: Analysis of enzyme processivity, chain-terminator removal and viral replication","volume":"6","author":"Naeger","year":"2001","journal-title":"Antivir. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/JVI.74.4.1704-1711.2000","article-title":"Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques","volume":"74","author":"Rosenwirth","year":"2000","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/JVI.74.4.1767-1774.2000","article-title":"Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA","volume":"74","author":"Miller","year":"2000","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1081\/NCN-100002496","article-title":"Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood","volume":"20","author":"Eisenberg","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.33696\/immunology.2.015","article-title":"Tenofovir at the crossroad of the therapy and prophylaxis of HIV and HBV infections","volume":"2","year":"2020","journal-title":"J. Cell. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1021\/ja043045z","article-title":"Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents","volume":"127","author":"Wu","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"24","author":"Andrei","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1135\/cccc2011065","article-title":"Acyclic nucleoside phosphonates: An unfinished story","volume":"76","year":"2011","journal-title":"Collect. Czechoslov. Chem. Commun."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:45Z","timestamp":1760168325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["v13122410"],"URL":"https:\/\/doi.org\/10.3390\/v13122410","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}